Drugs / HRS9531
Trials 32 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT06506175 | Jul → Sep 2026 expected | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07540754 | May 2026 → Jan 2027 expected | diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07559136 | May 2026 → Jan 2027 expected | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07150962 | Oct 2025 → Feb 2026 overdue | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06855147 | Apr → Jun 2025 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06762600 | Jan 2025 → Mar 2026 | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06723691 | Dec 2024 → Jun 2025 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06654960 | Nov → Dec 2024 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06435676 | Jun → Oct 2024 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06246175 | Feb 2024 → Sep 2025 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05893576 | May → Sep 2023 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05516966 | Oct 2022 → May 2023 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05152277 | Dec 2021 → Aug 2022 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07599410 | Jul 2026 → May 2027 expected | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07660848 | Jul 2026 → Mar 2028 expected | metabolic dysfunction-associated steatohepatitis | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06841445 | Apr 2025 → Jan 2026 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06595797 | Sep 2024 → Dec 2025 overdue | polycystic ovary syndrome | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06565871 | Aug 2024 → Dec 2025 overdue | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06391710 | May 2024 → Jan 2026 overdue | diastolic heart failure | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06287437 | Jan 2024 → Jun 2025 | obesity disorder | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06054698 | Oct 2023 → Sep 2024 | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05966272 | Aug 2023 → Sep 2024 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05881837 | Jun 2023 → Oct 2024 | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07670884 | Jul 2026 → Jul 2027 expected | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07551492 | May 2026 → May 2031 expected | atherosclerotic cardiovascular disease | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07285902 | Dec 2025 → Mar 2027 expected | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06994650 | Aug 2025 → Dec 2026 expected | obstructive sleep apnea syndrome | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07060456 | Jul 2025 → Feb 2027 expected | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06974851 | Jul 2025 → Dec 2026 expected | obstructive sleep apnea syndrome | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06650007 | Nov 2024 → Jan 2026 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06649344 | Oct 2024 → Sep 2026 expected | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06396429 | May 2024 → Jul 2025 | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS9531 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05152277 ↗31 |
| Route | Subcutaneous | “Administered SC once” NCT05152277 ↗ |